Mark B Juckett MD MHCM
Hematologic Oncology
Professor of Medicine Division Hematology & Medical Oncology
Join to View Full Profile
420 Delaware St SEMMC 480Minneapolis, MN 55455
Phone+1 612-624-6104
Dr. Juckett is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mark Juckett is a hematologist based in Minneapolis, MN, specializing in hematologic oncology. He earned his MD from the University of Louisville School of Medicine in 1987 and completed his fellowship in hematology and medical oncology at the University of Minnesota. He currently serves as a professor at the University of Minnesota, and is the Medical Director of the Bone Marrow Transplant and Cell Therapy program. Dr. Juckett is experienced in acute leukemia, myelodysplastic syndrome, myeloproliferative disorders, multiple myeloma, bone marrow failure syndromes, and hematopoietic stem cell and bone marrow transplantation. His research is published in several journals, and he is involved in multiple clinical trials. He holds numerous CMS Meaningful Use Stage 2 Certifications from Epic Systems Corporation.
Education & Training
Harvard School of Public HealthMasters of Healthcare Management, 2017 - 2019
University of MinnesotaFellowship, Hematology and Medical Oncology, 1991 - 1994- University of MinnesotaResidency, Internal Medicine, 1987 - 1990
University of Louisville School of MedicineClass of 1987
Vanderbilt UniversityBA, Psychology, 1983
Certifications & Licensure
WI State Medical License 1994 - 2027
MN State Medical License 2020 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
Clinical Trials
- Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Start of enrollment: 2002 Sep 01
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
- Belinostat in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 May 01
Publications & Presentations
PubMed
- Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.Shernan G Holtan, Punita Grover, Kelly Walton, Najla El Jurdi, Victoria Quinones
Blood Advances. 2026-04-14 - Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective.Eleanor Cook, Seth J Rotz, Jeffery J Auletta, Alan Bidgoli, Robyn Blacken
Pediatric Blood & Cancer. 2026-03-01 - 1 citationsAccess to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.Jason G Dehn, Brent Logan, Stephanie J Lee, Bronwen E Shaw, Steven Devine
Transplantation and Cellular Therapy. 2026-03-01
Journal Articles
- What is the value of the computer to the physician?MB Juckett, JS Spratt, Journal of Surgical Oncology 34:1-5
- Iron chelation impairs clonogenic survival and enhances gamma radiation induced injury of endothelial cells.MB Juckett, A Zheng, J Shadley, Radiation Research 149: 330-337
- Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction.CJ Link, RK Burt, AE Traynor, WR Drobyski, T Seregina, JP Levy, L Gordon, ST Rosen, WH Burns, B Camitta, J Casper, M Horowitz, M Juckett, C Lawton, D Margolis, D Pietr..., Human Gene Therapy 9(1):115-34
Abstracts/Posters
- Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults.WH Navarro, MA Agovi, B Logan, A Bacigalupo, KK Ballen, BJ. Bolwell, H Frangoul, V Gupta, T Hahn, M Juckett, HM. Lazarus, MR. Litzow, J Liesveld, J Moreb, D Marks, PL..., Blood (ASH Annual Meeting Abstracts)
- Generation of Epstein Barr Virus-Specific T cell lines from Patient Blood Post Bone Marrow and Solid Organ Transplantation.CA Keever-Taylor, RJ Orentas, M Juckett, J Casper, D Margolis, B Davies, S Konings, P Rivers, and W Burns, International Society for Hematotherapy and Graft Engineering Meeting., San Diego, CA
- Anti-CD20 Monoclonal antibody treatment for post-transplant B-cell lymphoma.N Siddiqi, M Juckett, R Orentas, B Bresnahan, S Hariharan, Joint Meeting of the American Society of Transplant Surgeons and the American Society of ...., Chicago, IL
Lectures
- Adult and Pediatric BMT61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Introduction to Practice-Improvement Modules.American Society of Blood and Marrow Transplantation
Grant Support
- Zosuquidar Trihydrochloride In Newly Diagnosed AMLNational Center For Research Resources2006
- Heme &Endothelium Effects Of Nitric Oxide On Catalytic IronNational Center For Research Resources1998–2001
- Nitric Oxide And Ferritin Mediated Tumor Cell ResistanceNational Cancer Institute1996–2000
- Control Of Heme And Release Of Active IronNational Center For Research Resources1999
- Nitric Oxide Inhibits Catabolism Of Cellular HemeNational Center For Research Resources1997
Professional Memberships
- Member
- American Society of Transplantation and Cellular TherapyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
